• Publications
  • Influence
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
TLDR
Through 144 weeks, the combination of tenofovir DF, lamivudine, and efavirenz was highly effective and comparable with stavudine for antiretroviral-naive patients and appeared to be associated with better lipid profiles and less lipodystrophy. Expand
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
TLDR
The combination of tenofovir DF and emtricitabineplus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efvirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs. Expand
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
TLDR
Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravIR in this treatment-experienced patient group. Expand
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind,
TLDR
Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide or E-C-F-tenofavir disoproxil fumarate and the main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the US Food and Drug Adminstration snapshot algorithm and pre-specified renal and bone endpoints at 48 weeks. Expand
Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical
TLDR
These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design. Expand
Episodic Sexual Transmission of HIV Revealed by Molecular Phylodynamics
TLDR
Reconstruction of the HIV transmission network using a dated phylogeny approach has revealed the HIV epidemic among MSM in London to have been episodic, with evidence of multiple clusters of transmissions dating to the late 1990s, a period when HIV prevalence is known to have doubled in this population. Expand
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012
TLDR
These guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection and at community advocates responsible for promoting the best interests and care of HIV-positive adults. Expand
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
TLDR
Results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach for HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Expand
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis
TLDR
Cumulative results from 3 years of follow-up suggest that a regimen of TDF/FTC andEFV demonstrates superior durability of viral load suppression and an improved safety and morphologic profile compared with ZDV/3TC and EFV. Expand
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
TLDR
Although the use of HAART led to significant reductions in viral load, ADI and mortality, co-infected patients commonly experienced AE leading to interruptions in TB/HIV therapy, and it is recommended to start HAART early for patients with advanced HIV disease and deferring HAART until the continuation phase of TB therapy for patients who are clinically stable. Expand
...
1
2
3
4
5
...